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Summary	
	Malaria	 remains	 one	 of	 the	 most	 devastating	 infectious	 diseases	 and	 despite	 the	current	 therapies	 are	 efficient,	 the	 WHO	 recommends	 Artemisinin	 Combination	Therapies	(ACTs)	as	the	frontline	treatments	against	P.	falciparum	malaria	to	limit	the	artemisinin	resistance.	Unfortunately,	 in	 the	Greater	Mekong	subregion,	 the	efficacy	of	 artemisinin-based	 combined	 therapies	 (ACTs)	 has	 recently	 been	 questioned	 by	resistance	to	both	artemisinin	derivatives	and	to	the	partner	drugs.	Recently,	a	new	mechanism	 of	 action	 based	 on	 the	 release	 of	 denatured	 haemoglobin	 products	(haemichromes),	bound	to	erythrocyte	membrane	through	the	cytoplasmic	domain	of	the	AE1	 (Band	3	protein)	has	been	characterized.	More	 specifically	phosphorylated	band	 3	 becomes	 uncoupled	 from	 the	 cytoskeleton,	 leading	 to	 the	 formation	 of	membrane	clusters	containing	haemichromes	–	band	3	aggregates	that	can	either	be	released	from	red	blood	cells	as	microvesicles	or	picked	by	spleen	macrophages	by	a	mechanism	known	 as	 erythrocyte	 pitting.	 This	 process	 is	mediated	 by	 erythrocytic	Syk	kinase	that	carries	out	the	Tyr	phosphorylation	of	band	3.		The	 consequent	 destabilization	 of	 the	 membrane	 is	 thought	 to	 be	 essential	 for	parasite	egress	from	the	red	cell	at	the	end	of	the	parasite’s	life	cycle,	since	inhibitors	of	 the	 Syk	 tyrosine	 kinase	 block	 band	 3	 tyrosine	 phosphorylation,	 membrane	weakening	and	parasite	reinfection.	
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In	silico	studies	were	based	on	different	approaches	of	molecular	modelling	(docking,	molecular	dynamics	and	virtual	screening).	In	presence	of	Syk	inhibitors	we	observed	a	marked	decrease	of	band	3	phosphorylation,	proportional	 to	 the	 increase	of	drug	dosage.	The	proteomic	data	about	the	IC50	values	follow	the	same	trend	in	relation	to	the	 computational	 analyses	 results.	 These	 studies	 enabled	 us	 to	 better	 analyse	 the	structure	of	different	Syk	inhibitors	and	to	possibly	discover	new	molecules	through	virtual	screening	analysis.	In	the	long	term,	we	aim	to	further	investigate	the	efficacy	of	these	compounds	by	evaluating	their	inhibitory	activity	through	proteomic	and	in	
vitro	studies.															
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1.1	Background	and	epidemiology	of	Malaria		Malaria	is	a	parasitic	disease	caused	by	a	protozoa	emosporidae	belonging	at	genus	 of	 plasmodium.	 This	 infective	 disease	 is	 transmitted	 by	 the	 female	Anopheles	mosquito	 bite,	which	 lives	mainly	 in	 the	 region	with	 a	 temperate	and	hot	climate.	Among	all	studied	mosquitoes	species,	only	 few	of	 them	are	responsible	of	malaria	disease,	whereas	the	others	are	harmless,	as	they	prefer	animal	blood	compared	to	human	blood.	The	main	vector	responsible	of	malaria	in	the	Afrotropical	region	is	Anopheles	Gambiae	specie	(Fig.1).		In	the	past	few	years,	the	disease	has	spread	through	the	western	continents	even	 though	 it	 has	 been	 eradicated	in	 these	 regions	 few	 years	 ago.	 The	migrants	 fluxes	 have	 been	 claimed	as	 a	 possible	 cause	 of	 this	unexpected	event.		Malaria	 is	 an	 infective	 disease	 that	causes	 a	 high	 level	 of	 deaths	 in	 the	world.	 The	 2017	 Malaria	 report	 of		registered	 216	 million	 new	 cases	and	455	thousands	dead.	Over	77	%	of	 children	die	with	 severe	 cerebral	damages	 and	 convulsions	 under	 5	years	 old	 (around	 300	 thousands),	 for	 this	 reason	malaria	 is	 also	 known	 as	“disease	 of	 childhood”	 [1].	 The	 sub-Saharan	 region	 is	 the	 most	 malaria	endemic	area	in	the	world	registering	around	90%	of	cases	in	the	world.	The	number	of	Plasmodium	falciparum	malaria	cases	has	rapidly	decreased	in	the	last	five	years	[2].	In	the	period	2011-2016	have	been	registered	3600	cases	in	Italy	mainly	due	to	the	migratory	fluxes.		Malaria	remains	one	of	the	most	devastating	infectious	diseases	in	the	world,	thereby	the	main	effort	consists	in	eradicate	it.		This	disease	 is	endemic	 in	103	nation	 therefore	many	people	are	exposed	 to	this	kind	of	pathology.	Malaria	affects	also	pregnant	women	and	infants,	who	
Fig.	1.	Female	Anopheles	mosquito	
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1.2	Malaria	parasite	life	cycle	and	P.	falciparum	The	malaria	parasite	life	cycle	involves	two	hosts.	As	shown	in	figure	3,	during	a	 blood	 meal,	 a	 malaria-infected	 female	 Anopheles	 mosquito	 inoculates	sporozoites	 into	 the	 human	 host	 1.	 The	 sporozoites	 infect	 liver	 cells	 2	 and	mature	into	schizonts	3,	with	consequent	rupture	of	membrane	and	release	of	merozoites	4.	In	P.	vivax	and	P.	ovale	a	dormant	stage	[hypnozoites]	can	persist	in	 the	 liver	 and	 cause	 relapses	 by	 invading	 the	 bloodstream	weeks,	 or	 even	years	later.		After	 this	 initial	 replication	 in	 the	 liver	 (exo-erythrocytic	 schizogony	A),	 the	parasites	 undergo	 asexual	 multiplication	 in	 the	 erythrocytes	 (erythrocytic	schizogony	B).	Merozoites	infect	red	blood	cells	5.	The	ring	stage	(1-24	hours)	and	 trophozoites	 (24-36	 hours)	 mature	 into	 schizonts	 (36-48	 hours),	 with	lysis	of	red	blood	cells	(RBCs)	membrane	(Fig.2)	and	release	of	merozoites	6.		Some	parasites	differentiate	into	sexual	erythrocytic	stages	(gametocytes)	7.																		 			 Fig.	2.	Intraerythrocytic	cycle	of	parasite	
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Blood	 stage	 parasites	 are	 accountable	 for	 the	 clinical	 manifestations	 of	 the	disease.	 The	 gametocytes,	 male	 (microgametocytes)	 and	 female	(macrogametocytes),	 are	 ingested	 by	 an	Anopheles	 mosquito	 during	 a	 blood	meal	8.	The	parasites	proliferation	in	the	mosquito	is	known	as	the	sporogonic	cycle	 C.	 At	 the	 same	 time,	 in	 the	 mosquito’s	 stomach,	 the	 microgametes	penetrate	 the	 macrogametes	 generating	 the	 zigotes	 9.	 The	 zygotes	 in	 turn	become	motile	and	elongated	(ookinetes)	10	which	invade	the	midgut	wall	of	the	mosquito	where	they	develop	into	oocysts	11.	The	oocysts	grow,	rupture,	and	release	sporozoites	12,	which	make	their	way	to	the	mosquito’s	salivary	glands.	 Inoculation	 of	 the	 sporozoites	1	 into	 a	 new	human	 host	 perpetuates	the	malaria	life	cycle	(Fig.3)	[7].			
	
	
	 													 The	 activation	 of	 parasite	 metabolic	 processes	 inside	 the	 RBCs,	 triggers	alterations	 of	 host	 cell	 energetic	 metabolism,	 deep	 proteins	 and	 membrane	structural	 changes.	 An	 example	 in	 P.	 falciparum	 consists	 of	 molecules	
Fig.	3.	Sexual	and	asexual	life	cycle	of	plasmodium	
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expression	 on	 the	 erythrocytes	 external	 surface	 that	 mediates	 the	 infected	RBCs	process	of	adhesion	to	the	endothelial	cells	in	capillary	of	some	organs.	This	phenomenon,	known	as	 “abduction”,	 represents	an	essential	pathogenic	mechanism	in	P.	falciparum	severe	malaria.	Malaria	parasites	use	haemoglobin	(hereafter	 referred	 to	 as	 Hb)	 as	 a	 major	 nutrient	 source	 in	 the	intraerythrocytic	 stage,	 during	 which	 the	 heme	 group	 is	 converted	 to	hemozoin	(hereafter	referred	to	as	Hz),	which	is	essential	for	parasite	survival	[8].	Mature	 trophozoites	digest	 the	haemoglobin	and	metabolize	 the	glucose,	through	 the	 anaerobic	 glycolysis.	 An	 infected	RBC	 increases	 of	 50-100%	 the	consumption	of	glucose	with	the	production	of	lactic	acid.	The	degradation	of	Hb	occurs	in	a	specialized	parasite	organelle	called	the	food	vacuole.	A	number	of	 studies	 have	 suggested	 that	Hb	 degradation	 is	 a	 cooperative	 process	 that	involves	 proteases	 of	 multiple	 catalytic	 classes,	 including	 cysteine,	 aspartic,	and	metallo	 proteases	 [9].	 These	 proteases	 produce	 short	 peptides	 that	 are	further	 degraded	 to	 amino	 acids,	 probably	 by	 aminopeptidases	 [10].	 During	the	 process	 of	 Hb	 degradation,	 heme	 group	 released	 in	 the	 food	 vacuole	 is	toxic	to	Plasmodium,	as	it	induces	oxygen-derived	free	radical	formation,	lipid	peroxidation	and	protein	and	DNA	oxidation.	Organisms	such	as	Plasmodium,	
Schistosoma,	 and	Rhodnius,	which	 use	Hb	 as	 a	 nutrient	 source,	 have	 evolved	different	strategies	to	detoxify	this	free	heme	group.	Plasmodium	spp.	converts	the	heme	group	to	β-hematin,	which	 is	a	dark	brown	pigment	also	known	as	Hz,	 through	 a	 process	 that	 is	 essential	 for	 the	 life	 cycle	 of	 these	 organisms	[14,15].	Hz	 is	 a	 cyclic	dimer	of	 ferriprotoporphyrin	 IX	 [Fe(III)PPIX]	 in	which	the	 propionate	 group	 of	 each	 Fe(III)PPIX	 molecule	 coordinates	 the	 Fe(III)	centre	of	its	partner	[15].	The	formation	of	mature	schizonts	containing	a	variable	number	of	merozoites	(24-32),	entails	their	release	and	the	lysis	of	erythrocytes.	This	process	occurs	every	 48h	 corresponding	 with	 the	 parasite	 life	 cycle.	 During	 this	 event,	 the	first	 clinic	 symptoms	 of	 the	 disease	 are	 shown:	 the	 characteristic	 fever	‘malignant	tertian’	in	P.	falciparum,	‘benign	tertian’	in	P.	vivax	and	P.	ovale	and	‘quartan’	in	P.	malariae	(Fig	4.).		
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1.3.1.	Genetic	Factors	Biologic	characteristics	present	from	birth	can	protect	against	certain	types	of	malaria.	Two	genetic	factors,	both	associated	with	human	red	blood	cells,	have	been	 shown	 to	 be	 epidemiologically	 important	 [13].	 People	 who	 have	 the	sickle	 cell	 trait	 (heterozygotes	 for	 the	 abnormal	 haemoglobin	 gene	HbS)	 are	relatively	 protected	 against	 P.	 falciparum	 malaria	 and	 therefore,	 hold	 a	biologic	advantage.	As	P.	falciparum	malaria	has	been	a	leading	cause	of	death	in	Africa	since	remote	times,	the	sickle	cell	trait	is	now	more	frequently	found	in	 this	 region	 and	 in	 people	 of	 African	 ancestry	 than	 in	 other	 population	groups.	In	general,	the	prevalence	of	haemoglobin-related	disorders	and	other	blood	 cell	 dyscrasias,	 such	 as	 Hemoglobin	 C,	 the	 thalassemia	 and	 G6PD	deficiency,	 are	more	 prevalent	 in	malaria	 endemic	 areas	 and	 are	 thought	 to	provide	protection	from	malarial	disease.	Other	genetic	factors	related	to	red	blood	cells	also	influence	malaria	but	with	a	 minor	 impact.	 Various	 genetic	 determinants	 (such	 as	 the	 “HLA	 complex,”	which	plays	a	role	in	control	of	 immune	responses)	may	equally	influence	an	individual’s	risk	of	developing	severe	malaria.	
	
1.3.2.	Acquired	Immunity	Acquired	immunity	greatly	influences	how	malaria,	affects	an	individual	and	a	community	 [13].	 After	 repeated	 malaria	 infections	 a	 person	 may	 develop	 a	partially	protective	 immunity	 (Fig.5).	Such	“semi-immune”	persons	often	can	
Fig.	4.	Fever	cycle	in	in	different	kind	of	plasmodium		
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• and	 finally	 a	 sweating	 stage	 (sweats,	 return	 to	 normal	 temperature,	tiredness).	Usually	 attacks	 occur	 every	 second	 day	 with	 the	 “tertian”	 parasites	 (P.	







• General	malaise	In	 countries	 where	 cases	 of	malaria	 are	 infrequent,	 these	symptoms	 may	 be	 attributed	 to	influenza,	cold,	or	other	common	infections,	especially	if	malaria	is	not	 suspected.	 On	 the	 other	 hand,	 in	 countries	 where	 malaria	 is	 frequent,	Fig.	6.	Main	symptoms	of	malaria	
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1.4.1.1.	Incubation	Period	Following	the	infective	bite	by	the	Anopheles	Mosquitos	a	period	of	time	(the	“incubation	 period”)	 elapses	 before	 the	 first	 symptoms	 appear	 (Tab.1).	 The	incubation	period	in	most	cases	varies	from	7	to	30	days.	The	shortest	periods	are	observed	most	frequently	with	P.	falciparum	and	the	longest	ones	with	P.	
malariae.	Antimalarial	drugs	used	 for	prophylaxis	purposes	by	 travellers	can	delay	 the	appearance	of	malaria	symptoms	by	weeks	or	months,	long	after	the	traveller	has	left	the	malaria-endemic	area.	(This	can	happen	particularly	with	P.	vivax	and	P.	ovale,	both	of	which	can	produce	dormant	liver	stage	parasites;	the	liver	stages	may	reactivate	and	cause	disease	months	after	 the	 infective	mosquito	bite.)									 	
		 		Plasmodium	species	
		 	P.	vivax	 P.	ovale		 P.	malariae		 P.	falciparum		
Pro-erythrocytic	
phase	(days)	 6-8	 9	 14-16	 5-7	
Erythrocytic	cycle	
(hours)	 48	 50	 72	 48	
Incubation	period	
(days)	
12-17	or	even	6-12	months	 16-18	or	more	 18-40	or	more	 9-14	
Sporogony	(days)	 8-10	 12-14	 14-16	 9-10	
Tab.	1.	Period	of	incubation	in	different	species	of	plasmodium	
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Such	long	delays	between	exposure	and	development	of	symptoms	can	result	in	misdiagnosis	or	delayed	diagnosis	due	to	reduced	clinical	suspicion	by	the	health-care	provider.	Returned	 travellers	should	always	remind	 their	health-care	providers	of	any	travel	in	areas	where	malaria	occurs	during	the	past	12	months.	
	








• Hyperparasitemia,	 where	 more	 than	 5%	 of	 the	 red	 blood	 cells	 are	infected	by	malaria	parasites	
• Metabolic	acidosis	(excessive	acidity	in	the	blood	and	tissue	fluids),	often	in	association	with	hypoglycaemia	
• Hypoglycaemia	 (low	 blood	 glucose).	 Hypoglycaemia	 may	 also	 occur	 in	pregnant	 women	 with	 uncomplicated	 malaria,	 or	 after	 treatment	 with	quinine.	
• 	
1.4.3.	Cerebral	malaria		Despite	decades	of	research,	cerebral	malaria	remains	one	of	the	most	serious	complications	 of	 Plasmodium	 infection	 [17].	 The	 erythrocytes	 infected	 by	parasite	 in	 the	 microcirculation,	 especially	 cerebral	 circulation	 have	 a	tendency	 to	 accumulate,	 forming	 “rosette”	 (on	 the	 surface	 are	 present	
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1.5.	Erythrocytes	plasmatic	membrane		The	 RBCs	 plasmatic	 membrane	 is	 constituted	 for	 50%	 of	 protein	 (mainly	intrinsic),	40%	of	lipids	and	10%	of	carbohydrate.	The	erythrocyte	is	different	from	 the	 other	 cells	 since	 the	 cytoskeleton	 forms	 a	 shell	 to	 support	 the	plasmatic	membrane.		
	
1.5.1.	Red	blood	cells	plasmatic	membrane	structure	Protein	Band	3	(Anion	Exchange	1)	is	the	main	protein	(25%)	in	the	red	blood	cells	membrane,	 involved	 in	different	cell	process.	 Its	molecular	weight	 is	95	KDa	and	it	can	exist	in	monomeric,	dimeric,	tetrameric	form	or	aggregates	[18].	In	the	red	blood	cells,	the	Band	3	mediates	the	anionic	exchange	between	the	bicarbonate	ion	(HCO3	-)	presents	in	cytoplasm	and	ion	chloride	(Cl-)	presents	in	the	plasma	(Fig.	8).		The	bicarbonate	 ion	 is	 involved	 in	 the	 following	 reaction	 catalysed	 from	 the	carbonic	anhydrase.		
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The	protein	Band	3	(Fig.	9)	is	composed	of	a	transmembrane	domain	and	two	cytoplasmic	 domains	 [19].	 Each	 protein	 domain	 has	 precise	 and	 different	cellular	functions:	
-		 The	 transmembrane	 hydrophobic	 domain	 is	 a	 region	 of	 52KDa,	includes	 the	 aminoacidic	 residues	 360-911,	 dipped	 in	 the	 bilayer	phospholipidic	 forming	 a	 series	 of	 12-14	 folding.	 This	 domain	 lead	 to	 the	formation	 of	 an	 anionic	 channel	 that	 allows	 the	 Exchange	 of	 Cl	 -	 and	HCO3	–		among	the	external	and	internal	of	cell.		
-	 The	 N-terminal	 hydrophilic	 domain	 (cytoplasmic	 domain),	 of	43KDa,	includes	the	aminoacidic	residues	1-359,	known	as	cytosolic	domain	of	Band	3	(cdb3).	 It	penetrates	 in	the	cytosol	playing	a	role	of	anchorage	to	the	cytoskeleton	and	for	some	protein	as	haemoglobin	and	aldolase.		
-	 The	C-terminal	hydrophilic	domain	includes	the	last	33	aminoacidic	residues	directed	towards	the	cytoplasm.		At	 the	N-terminal	 domain	 can	bind	different	 kind	of	 proteins	 including	 the	ankyrin	and	Band	4.1	and	4.2	that	characterize	the	erythrocyte	shape.		 																 Fig.	 9.	 Model	 of	 human	 erythrocyte	 band	 3.	 The	 protein	 contains	 2	 structurally	 and	functionally	 distinct	 domains:	 a	 cytoplasmic	 binding	 domain	 (amino	 acids	 1-359)	 and	 a	
transmembrane	domain	(amino	acids	360-911)	that	forms	the	anion-exchange	channel	
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1.6.	The	spleen	tyrosine	Kinase	(Syk)	Spleen	 tyrosine	kinase	 (Syk,	EC	2.7.10.2)	 is	a	cytosolic	non-receptor	 tyrosine	kinase	(Fig.13)	that	performs	its	function	downstream	of	antigen	receptors	in	immune	 cells	 such	 as	 mast	 cells,	 B-lymphocytes,	 or	 macrophages.	 Syk	 is	 a	crucial	 signal	 transducer	 of	 activated	 immunoreceptors	 to	 multiple	 events	depending	 on	 the	 cell	 types	 including	 proliferation,	 differentiation,	 and	phagocytosis	[23-26].	Inhibiting	this	protein	is	possible	to	avoid	all	cascade	of	events	 causing	 the	 onset	 of	 many	 disorders.	 Furthermore	 Syk	 is	 one	 of	 the	principal	 proteins	 involved	 in	 oxidative	 stresses	 processes.	 The	 therapeutic	intervention	 on	 mechanisms	 in	 which	 Syk	 is	 involved	 might	 provide	 an	attractive	target	for	autoimmune	or	inflammation	diseases	[27].		
Fig.	12.	Characteristic	network	structure	of	spectrin	in	RBCs	
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																					Syk	belongs	to	the	same	subfamily	as	the	closely	related	Zeta-chain-associated	protein	kinase	70	(ZAP-70).	The	Spleen	tyrosine	kinase	(72KDa)	is	composed	of	 two	 Src	 homology	 tandem	 domains	 defined	 N-SH2	 and	 C-SH2;	 these	 are	important	 for	 the	 activity	 regulation	 and	 to	 localize	 this	 kinase	 in	 cell	membrane	(Fig.14).			The	protein	consisting	of:		- a	 tandem	 SH2	 module	 (N-SH2	 and	 C-SH2),	 that	 presents	 an	 α-helix	which	has	an	important	role	in	the	interaction	protein-protein	and	serves	as	 a	 docking	 platform	 for	 immune	 receptor	 tyrosine-based	 activating	motifs	 (ITAMs)	 which	 are	 displayed	 on	 the	 cytosolic	 side	 of	 the	 plasma	membrane		
Fig.	 13.	 3D	 beta-sheet	 structure	 of	 Spleen	 tyrosine	 kinase	 (Syk)	 (PDB	 ID:	
4FL2).	 Represented	 with	 yellow	 is	 the	 N-SH2	 domain;	 cyan	 the	
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Fig.	 15.	 Graphical	 abstract	 of	 the	 mechanism,	 which	 leads	 to	 the	 release	 of	
microparticles	
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Artemisinin	 (ART)	 and	 its	 semi-synthetic	 derivatives	 are	 a	 group	 of	 drugs	used	 against	 Plasmodium	 falciparum	malaria	 [37].	 Treatments	 containing	 an	artemisinin	 derivative	 actually	 represent	the	 standard	 therapies	 worldwide	 for	 P.	
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1.7.1.1.	The	artemisinins	mechanism	of	action	The	mechanism	of	 action	 of	 artemisinins	 is	 not	 known,	 but	 the	most	widely	accepted	theory	is	that	they	are	first	activated	through	cleavage	after	reacting	with	heme	and	iron	(II)	oxide,	which	results	in	the	generation	of	free	radicals	that	in	turn	damage	susceptible	proteins,	resulting	in	the	death	of	the	parasite	[40,41].	 In	2016	artemisinin	was	shown	to	bind	to	a	 large	number	of	 targets	suggesting	that	it	acts	in	a	promiscuous	manner	[42].			
1.7.1.2.	Artemisinin	derivatives	Because	 the	 physical	 properties	 of	 artemisinin	 itself,	 such	 as	 poor	bioavailability,	limit	its	effectiveness,	semisynthetic	derivatives	of	artemisinin	have	been	developed.	These	include:		





Dihydroartemisinin	(Fig.18)	in	particular	(also	known	as	dihydroqinghaosu,	artenimol	or	DHA)	is	the	active	metabolite	of	all	 artemisinin	 compounds	 (artemisinin,	artesunate,	 artemether,	 etc.)	 and	 is	 also	available	 as	 a	 drug	 in	 itself.	 It	 is	 a	 semi-synthetic	 derivative	 of	 artemisinin	 and	 is	widely	 used	 as	 an	 intermediate	 in	 the	preparation	 of	 other	 artemisinin-derived	antimalarial	 drugs	 [43].	 It	 is	 sold	commercially	in	combination	with	piperaquine	(PPQ)	and	has	been	shown	to	be	equivalent	to	artemether/lumefantrine	(LMF)	[44].		The	 proposed	 mechanism	 of	 action	 of	 artemisinin	 involves	 cleavage	 of	endoperoxide	bridges	 by	 iron,	 producing	 free	 radicals	 (hypervalent	 iron-oxo	species,	 epoxides,	 aldehydes,	 and	 dicarbonyl	 compounds),	 which	 damage	
Fig.	18.	Structure	of	Dihydroartemisinin	
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biological	macromolecules	causing	oxidative	stress	in	the	cells	of	the	parasite	[45].	Malaria	 is	 caused	 by	 apicomplexans,	 primarily	 Plasmodium	 falciparum,	which	 largely	 reside	 in	 red	 blood	 cells	 and	 itself	 contains	 iron-rich	 heme-groups	(in	the	form	of	hemozoin)	[46].	In	2015	artemisinin	was	shown	to	bind	to	 a	 large	 number	 targets	 suggesting	 that	 it	 acts	 in	 a	 promiscuous	manner.	Recent	 studies	 discovered	 that	 artemisinin	 targets	 a	 broad	 spectrum	 of	proteins	 in	 the	 human	 cancer	 cell	 proteome	 through	 heme-activated	 radical	alkylation	[47].			












falciparum	 resistance	 to	 chloroquine,	 sulfadoxine-pyrimethamine,	 and	a	third	antimalarial	compound;		
• Treatment	 failure	 is	 the	 inability	 to	 clear	 parasites	 from	 a	 patient’s	blood	or	to	prevent	their	recrudescence	after	the	administration	of	an	antimalarial.	Many	factors	can	contribute	to	treatment	failure,	including	incorrect	dosage,	poor	patient	compliance,	poor	drug	quality,	and	drug	interactions	 and	 resistance.	 Most	 of	 these	 factors	 are	 addressed	 by	therapeutic	efficacy	studies.	In	 reporting	 the	 findings	 of	 therapeutic	 efficacy	 studies,	 the	 term	 "ACT	resistance"	 is	 imprecise.	 ACT	 treatment	 failure	 (defined	 as	 treatment	 failure	following	 treatment	 with	 an	 ACT,	 regardless	 of	 the	 presence	 of	 artemisinin	partial	resistance)	is	a	more	appropriate	term	that	notes	the	specific	ACT	and	the	nature	of	the	resistance	if	confirmed	(i.e.	artemisinin	partial	resistance	or	partner	drug	resistance,	or	both).	The	problem	of	antimalarial	drug	resistance	is	 compounded	 by	 cross	 resistance,	 in	which	 resistance	 to	 one	 drug	 confers	resistance	 to	 other	 drugs	 that	 belong	 to	 the	 same	 chemical	 family	 or	which	have	similar	modes	of	action.				
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1.9.1.	State	of	partial	artemisinin	resistance	around	the	world	Artemisinin	partial	 resistance	 likely	emerged	prior	 to	2001,	 and	prior	 to	 the	widespread	deployment	of	ACTs	in	the	GMS.	To	date,	it	has	been	confirmed	in	5	countries	 of	 the	 GMS:	 Cambodia,	 the	 Lao	 People’s	 Democratic	 Republic,	Myanmar,	Thailand	and	Viet	Nam.		In	late	2013,	researchers	identified	a	new	molecular	marker:	mutations	in	the	Kelch	13	 (K13)	propeller	domain	were	 shown	 to	be	associated	with	delayed	parasite	clearance	in	vitro	and	in	vivo	[48].	The	molecular	marker	allows	for	a	more	 precise	 mapping	 and	 monitoring	 of	 the	 geographical	 distribution	 of	resistance.	 It	 could	 also	 be	 a	 mechanism	 for	 retrospective	 mapping	 of	resistance	in	a	large	number	of	settings.	Parasites	carrying	mutations	in	the	K13	propeller	domain	have	been	reported	in	 all	 5	GMS	 countries	 listed	 above	 as	 well	 as	 in	 Guyana,	 where	 studies	 are	ongoing	 to	 evaluate	 impact	 of	 this	 mutation	 on	 delayed	 clearance	 and	 ACT	efficacy	and	its	potential	spread	within	and	outside	South	America.	Molecular	studies	have	shown	that	partial	artemisinin	resistance	has	emerged	independently	 in	 several	 locations	 in	 the	 GMS	 and	 spread	 within	 the	subregion.	 The	 K13	mutation	 identified	 in	 South	 America	 has	 also	 emerged	independently.	Artemisinin	partial	resistance	has	not	been	confirmed	in	Africa.	Partial	 artemisinin	 resistance	 has	 occurred	 as	 a	 consequence	 of	 several	factors:	poor	treatment	practices,	inadequate	patient	adherence	to	prescribed	antimalarial	 regimens,	 and	 the	 widespread	 availability	 of	 oral	 artemisinin-based	monotherapies	and	substandard	forms	of	the	drug.			
1.9.2.	Current	state	of	ACT	failures	Artemisinin	 resistance	 alone	 rarely	 leads	 to	 treatment	 failure.	 However,	resistance	 of	 malaria	 parasites	 to	 ACT	 partner	 drugs	 can	 lead	 to	 treatment	failure	 (regardless	 of	 the	 presence	 of	 artemisinin	 partial	 resistance).	 As	 a	consequence,	WHO	 in	 the	 2017	Malaria	 report	 showed	 the	maps	 of	 several	ACTs	that	are	failing	(Artesunate-Amodiaquine)	in	the	African	regions		(Fig.19)	and		Greater	Mekong	area	(Artemether-Lumefantrine),	(Fig.20).		The	geographic	scope	of	the	problem	could	widen	quickly	and	have	important	public	health	consequences:	the	spread	or	independent	emergence	of	partner	
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reason,	 the	 ACT	 is	 substituted	 from	 the	 standard	 therapy.	 The	 development	and	research	of	new	antimalarial	drugs	is	necessary	to	avoid	the	increasing	of	parasite	resistance.	A	promising	approach	in	the	antimalarial	therapy	consists	in	utilization	of	Syk	kinase	inhibitors	with	the	purpose	to	block	the	expulsion	of	 denatured	 haemoglobin	 and	 its	 accumulation	 inside	 the	 parasitized	erythrocytes	[50]	and	not	allow	the	growth	and	proliferation	of	plasmodium.		Moreover,	 an	 innovative	 method	 as	 molecular	 modelling	 appears	 an	interesting	 way	 to	 better	 understand	 and	 explain	 the	 biological	 mechanism	and	discover	some	molecules	able	to	inhibit	the	protein	target.	
	
1.10.	Computational	studies	to	explain	the	biological	phenomenon		In	 the	 last	 years,	 several	 researches	 about	 the	 in	 vitro	 experiments	 on	biological	mechanism	supplemented	of	computational	sciences	have	led	to	the	development	of	different	molecular	modelling	approaches.	Actually	is	possible	to	determine	several	molecules	conformation,	to	evaluate	the	free	energy	and	compounds	 energy	 of	 binding	 and	 calculate	 the	 molecular	 descriptors	(lipophilicity,	 molecular	 electrostatic	 potential,	 molecule	 volume,	 accessible	surface	 to	 the	 solvent	 and	molecular	 orbitals).	 Moreover,	 different	 software	has	 been	 developed	 in	 order	 to	 simulate	 the	 ligand-protein	 interaction,	protein-protein	 with	 or	 without	 solvent	 aimed	 to	 a	 rational	 drugs	 design.	These	 techniques,	 in	 a	 multidisciplinary	 approach,	 represent	 the	 interface	among	 chemistry,	 biology	 and	 computational	 science	 with	 the	 purpose	 to	study	 and	 deepen	 the	 interaction	 between	 the	 proteins	 and	 the	 ligand	with	low	molecular	weight	and	the	different	mechanism	of	action.		Many	 studies	 demonstrated	 that	 the	molecular	modelling	 can	 be	 a	 powerful	methodology	 for	 biomedical	 research,	 useful	 for	 analysing	 the	 three	dimensional	 structure	 of	 biological	 macromolecules	 with	 the	 aim	 to	 better	understand	 and	 explain	 the	 cell	 processes	 as	 well	 as	 for	 drug	 discovery	 in	pharmaceutical	science	and	research	in	bionanotechnology	[51-53].		 	 	The	main	approaches	used	in	molecular	modelling	for	studying	the	biological	systems	and	the	molecule	interacting	with	the	human	protein,	regard:	
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- Conformational	 analysis	 is	 necessary	 to	 determine	 the	 protein	 and	ligands	 conformations	 with	 the	 lowest	 energy	 and	 protein	 flexibility,	namely	 the	 more	 stable	 and	 with	 a	 better	 interaction	 in	 the	 biological	environment.	 For	 this	 reason,	 have	 been	 used	 techniques	 of	 Molecular	Mechanics	 (MM)	 that	 are	 involved	 in	 most	 of	 Computational	 Structure-Based	Drug	Discovery	(CSBDD)	projects	[54].		The	conformational	research	has	been	carried	out	using	the	compound	of	interest	seeking	the	minimum	conformational	(the	different	disposition	of	that	structure	in	the	space)	depending	from	the	number	of	different	simple	bond	 that	 are	 present	 in	 the	 molecule.	 	 This	 phase	 is	 even	 known	 as	“minimization”.		The	following	step	consist	on	the	computation	of	the	best	energy	(the	lowest	value)	using	the	Quantum	Mechanics	(QM),	which	is	the	science	 that	 explains	 the	 behaviour	 of	 matter	 and	 its	 interactions	 with	energy	on	the	scale	of	atoms	and	subatomic	particles.	This	method	allows	the	 computation	 of	 bond	 length,	 binding	 angles	 and	 charge	 density	with	short	 time	 for	 small	 molecules	 and	 longer	 time	 with	 more	 atoms	 in	compounds	[55].	- Virtual	 screening	 (VS)	 is	 a	 computational	 technique	 used	 in	 drug	discovery	to	search	 libraries	of	small	molecules	 in	order	to	 identify	 those	structures,	 which	 are	 most	 likely	 to	 bind	 to	 a	 drug	 target,	 typically	 a	protein	receptor	or	enzyme	[56-58].	Virtual	screening	has	been	defined	as	the	 "automatically	 evaluating	 very	 large	 libraries	 of	 compounds"	 using	computer	 programs.	 As	 this	 definition	 suggests,	 VS	 has	 largely	 been	 a	numbers	game	focusing	on	how	the	enormous	chemical	space	of	over	1060	conceivable	compounds	can	be	 filtered	 to	a	manageable	number	 that	 can	be	synthesized,	purchased,	and	tested	[59].	Although	searching	the	entire	chemical	 universe	 may	 be	 a	 theoretically	 interesting	 problem,	 more	practical	 VS	 scenarios	 focus	 on	 designing	 and	 optimizing	 targeted	combinatorial	 libraries	 and	 enriching	 libraries	 of	 available	 compounds	from	in-house	compound	repositories	or	vendor	offerings.	As	the	accuracy	of	the	method	has	increased,	virtual	screening	has	become	an	integral	part	of	the	drug	discovery	process	[60].		
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Virtual	Screening	can	be	used	 to	select	 in	house	database	compounds	 for	screening,	 choose	 compounds	 that	 can	 be	 purchased	 externally,	 and	 to	choose	which	compound	should	be	synthesized	next.		
Ligand-Based	Virtual	Screening	(LBVS)	Given	a	set	of	structurally	diverse	ligands	that	binds	to	a	receptor,	a	model	of	 the	 receptor	 can	 be	 built	 by	 exploiting	 the	 collective	 information	contained	 in	 such	 set	 of	 ligands.	 These	 are	 known	 as	 pharmacophore	models.	A	 candidate	 ligand	 can	 then	be	 compared	 to	 the	pharmacophore	model	to	determine	whether	it	is	compatible	with	it	and	therefore	likely	to	bind	[61].		A	popular	approach	to	ligand-based	virtual	screening	is	based	on	searching	molecules	with	shape	similar	 to	 that	of	known	actives,	as	such	molecules	will	fit	the	target's	binding	site	and	hence	will	be	likely	to	bind	the	target.		
	
Structure-Based	Virtual	Screening	(SBVS)	Structure-based	 virtual	 screening	 involves	 docking	 of	 candidate	 ligands	into	 a	 protein	 target	 followed	 by	 applying	 a	 scoring	 function	 to	 estimate	the	likelihood	that	the	ligand	will	bind	to	the	protein	with	high	affinity	[62-64].	Web	servers	oriented	to	prospective	virtual	screening	are	available	to	everyone	[65,66].		Structure-based	 VS	 for	 drug	 discovery	 (SBDD)	 is	 becoming	 an	 essential	tool	in	assisting	fast	and	cost-efficient	lead	discovery	and	optimization.	The	application	of	 rational,	 structure-based	drug	design	 is	proven	 to	be	more	efficient	 than	 the	 traditional	 way	 of	 drug	 discovery	 since	 it	 aims	 to	understand	the	molecular	basis	of	a	disease	and	utilizes	the	knowledge	of	the	three-dimensional	structure	of	the	biological	target	in	the	process.	- Docking	is	a	detailed	study	of	protein-ligand	or	protein-protein	interaction	aimed	 to	 explain	 their	 chemical	 behaviour	 and	 biological	 activity	 or	 give	more	information	about	unknown	mechanism	of	action.	The	disadvantage	of	 this	 method	 consists	 in	 the	 fact	 it	 cannot	 take	 in	 consideration	 the	concentration	of	compounds	such	as	in	the	in	vitro	studies.	For	this	reason,	the	in	silico	obtained	results	may	not	be	related	to	in	vitro	data.	The	protein	is	blocked	in	a	position	derivate	from	the	X-ray	crystal	structure	while	the	
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ligand	 is	 examined	 to	 see	 how	 it	 interacts	 with	 the	 protein	 once	 is	established	the	binding	site.	The	obtained	results	are	analysed	in	basis	on	how	 many	 times	 a	 single	 conformation	 of	 compound	 interacts	 with	 the	macromolecule	 in	 a	 precise	 site	 with	 a	 lowest	 value	 of	 Energy.	 In	 this	phase,	 the	 molecule	 can	 freely	 move	 in	 the	 protein	 changing	 its	conformation	to	better	adapt	to	binding	site	of	protein	but	is	not	possible	changing	 the	bonds	 length.	 	 For	 this	 reason	 is	 important	 to	 carry	out	 the	quantum	mechanics	 calculation	 in	 order	 to	 give	more	 information	 about	the	specific	bonds	length	[67].		- Molecular	 dynamics	 (MD)	 is	 a	 computational	 method	 for	 studying	 the	physical	 movements	 of	 atoms	 and	 molecules	 over	 time	 in	 which	 the	simulation	 is	 implemented	 from	 nanoseconds	 (ns)	 up	 to	 a	 maximum	 of	seconds	 (s)	 depending	 from	 the	 facilities	 used	 for	 the	 computation.	 The	interaction	 of	 atoms	 and	molecules	 is	 allowed	 for	 a	 fixed	 period	 of	 time,	giving	a	view	of	the	dynamic	evolution	of	the	system.	In	the	most	common	version,	 the	 trajectories	 of	 atoms	 and	 molecules	 are	 determined	 by	numerically	 solving	 Newton's	 equations	 of	 motion	 for	 a	 system	 of	interacting	 particles,	 where	 forces	 between	 the	 particles	 and	 their	potential	 energies	 are	 often	 calculated	 using	 interatomic	 potentials	 with	molecular	mechanics	force	fields.	Using	the	molecular	dynamic	we	observe	as	 the	molecules	move	 into	 the	protein	 site	of	 interaction	 surrounded	by	thousands	 of	 water	 molecules	 in	 order	 to	 simulate	 the	 biological	environment	[68].		Actually,	 the	 molecular	 modelling	 represents	 one	 of	 the	 fastest	 growing	fields	 in	 science.	 It	 may	 vary	 from	 building	 and	 visualizing	 simple	molecules	 in	 three	 dimensions	 (3D)	 to	 performing	 complex	 computer	simulations	on	large	proteins	and	nanostructures.	Molecular	modelling	is	a	collection	 of	 computer-based	 techniques	 for	 driving,	 representing	 and	manipulating	 the	 structures	 and	 reactions	 of	 molecules,	 and	 those	properties	 that	 are	 dependent	 on	 these	 3D	 structures.	 The	 techniques	 in	
silico	 cover	 several	 issues	 among	 them	 computational	 chemistry,	 drug	design,	computational	biology,	nanostructures,	and	material	science	[69].	
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The	so	far	carried	out	studies	 for	the	development	of	new	 in	silico	drugs	and	the	laboratory	tests	have	been	focused	on	different	molecules	that	can	be	used	as	possible	drugs	for	the	protein	complex	inhibition	needed	for	the	growth	and	proliferation	of	malaria	parasite	[70-72].		Computational	 studies	 conducted	 on	 protein	 kinases	 (Pks)	 of	 Plasmodium	
falciparum	 are	 of	 particular	 interest	 since	 they	 catalyse	 a	 reaction	 of	phosphorylation	to	control	the	parasite	growth	and	differentiation	throughout	its	life	cycle.			In	 2011	 started	 a	 new	 project	 known	 as	 GO	 (Global	 Online)	 Fight	 Against	Malaria	 belonging	 at	 the	 IBM	 (International	 Business	 Machines)	 World	Community	Grid.	At	 this	project	participated	 the	Art	Olson	Lab	of	TSRI	 (The	Scripps	Research	Institute)	in	San	Diego,	CA,	USA.	This	laboratory	is	one	of	the	leaders	 in	 this	 sector	 and	 its	 effort	 consists	 to	 discover	 promising	 drug	candidates	 that	 could	 be	 developed	 into	 new	 drugs	 that	 cure	 drug	 resistant	forms	 of	malaria.	 The	 computing	 power	 of	World	 Community	Grid	 has	 been	used	to	perform	computer	simulations	of	the	interactions	between	millions	of	chemical	 compounds	 and	 certain	 target	 proteins,	 to	 predict	 their	 ability	 to	eliminate	 malaria.	 The	 best	 compounds	 were	 tested	 and	 further	 developed	into	possible	treatments	for	the	disease.		Following	these	ideas,	we	developed	and	took	in	consideration	some	chemical	compound.	 The	 host	 target	 Drug	 resistance	 arguably	 constitutes	 the	 biggest	problem	faced	in	the	field	of	infectious	diseases	today	and	is	a	major	obstacle	to	 the	 development	 of	 effective	 strategies	 to	 combat	 infection.	 Pathogens,	particularly	 those	 with	 an	 intracellular	 habitat,	 exploit	 and	 subvert	 various	host	 factors	 for	survival	and	growth	 in	an	otherwise	hostile	environment.	As	such,	one	possible	way	to	circumvent	the	emergence	of	a	pathogen’s	resistance	is	 to	 develop	 drugs	 that	 target	 non-essential	 host	 factors	 hijacked	 by	 the	pathogen	rather	than	the	pathogens	own	molecules.	Indeed,	host	proteins	are	generally	well	conserved,	when	compared	with	the	genetic	variability	of	many	pathogens	[74].			
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1.11.1.	Kinase	inhibitors	mainly	used	in	therapy	
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P505-15:4-((3-(2H-1,2,3-triazol-2-yl)phenyl)amino)-2-(((1R,2S)-2-amino-cyclohexyl)amino)pyrimidine-5-carboxamide-hydrochloride	 (Fig.24).	 It 	 is	 a	novel,	highly	selective	Syk	inhibitor	with	IC50	of	1	nM	in	cell-free	assays,	>80-fold	 selective	 for	 Syk	 than	 Fgr,	 Lyn,	 FAK,	 Pyk2	 and	 Zap70.	 Candidate	 drug	already	used	in	vivo	studies	in	mices	for	rheumatoid	arthritis	and	used	for	the	treatment	 of	 non-Hodgkin	 lymphoma	 (NHL)	 and	 chronic	 Lymphocytic	Leukaemia	(CLL)		[82,83].			 							
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Another	 Syk	 inhibitor	 has	 been	 taken	 in	 consideration	 but	 with	 less	importance	considering	the	 low	inhibition	efficacy	 in	vitro	tests,	although	the	IC50	 concentration	 of	 enzymatic	 assay	 reported	 in	 literature	 shows	 a	 highly	potent	compound.		
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2.	Aim	of	the	project		Recently,	a	new	phosphorylative	pathway	involved	in	the	release	of	denatured	haemoglobin	 products	 (haemichromes),	 bound	 to	 erythrocyte	 membranes	through	 the	 cytoplasmic	 domain	 of	 the	 AE1	 (band	 3	 protein),	 has	 been	characterized.	Tyr	phosphorylation	of	the	band	3	protein	carried	out	mainly	by	the	 erythrocytic	 Syk	 kinase	 mediates	 this	 process.	 Phosphorylated	 band	 3	becomes	 uncoupled	 from	 the	 cytoskeleton,	 leading	 to	 the	 formation	 of	membrane	 clusters	 containing	 haemichromes	 –	 band	 3	 aggregates	 that	 can	either	be	 released	 from	 red	blood	 cells	 as	microvesicles	 or	picked	by	 spleen	macrophages	 by	 a	 mechanism	 known	 as	 erythrocyte	 pitting.	 These	mechanisms	may	be	responsible	 for	 the	elimination	of	noxious	aggregates	of	denatured	 haemoglobin;	 indeed,	 during	 their	 120-day	 lifespan,	 erythrocytes	undergo	 dramatic	 changes,	 eliminating	 approximately	 30%	 of	 the	 initial	haemoglobin	 content	 of	 the	 membrane	 surface.	 Moreover,	 it	 has	 been	observed	 that	 those	 modifications	 are	 an	 essential	 prerequisite	 for	 parasite	egression	 from	 the	 host	 cell	 constituting	 the	 theoretical	 background	 of	 the	observed	 anti-plasmodial	 activity	 of	 Syk	 inhibitors.	 Due	 to	 the	 mechanism	describe	 above,	 in	 the	 present	 thesis	 the	main	 purpose	 consists	 in	 studying	and	 understanding	 the	 effects	 of	 different	 Syk	 inhibitors	 on	 critical	 events	during	parasite	growth	and	maturation	within	the	human	erythrocyte.		In	particular,	 the	central	 concept	was	 to	 leverage	 in	vitro	and	computational	tools	to	allow	efficient	therapy	using	Syk	inhibitors	and	targeting	the	host	red	blood	 cell	 instead	 of	 parasite,	 in	 order	 to	 interfere	 with	 the	 growth	 and	reinfection	 capability	 of	 parasite.	 Taking	 in	 consideration	 that	 Syk	 inhibitors	block	the	phosphorylation	events,	is	necessary	to	have	more	knowledge	on	the	mechanisms	 responsible	 of	 the	 protein-ligand	 recognition	 and	 binding,	 in	order	 to	 facilitate	 the	 design,	 development	 and	 discovery	 of	 new	 promising	class	of	 antimalarial	 drugs.	A	detailed	 analysis	 of	 Syk	 /ligand	 interactions	 is,	therefore	the	central	focus	in	order	to	understanding	the	biological	process	at	the	molecular	 level,	also	obtaining	useful	 information	on	 the	pharmacophore	structure	of	Syk	inhibitors.	Finally,	this	research	has	the	purpose	to	prevent	as	much	 as	 possible	 the	 drug	 resistance	 by	 Plasmodium,	 improving	 and	modifying	 the	 compounds	 structure	or	 screen	new	molecules	with	a	 specific	
	 	 Aim	of	the	project	
Giuseppe	 Marchetti;	 “In	 vitro	 and	 in	 silico	 studies	 of	 Syk	 inhibitors	 as	 new	 antimalarial	 drugs”;	Doctoral	thesis	in	Life	Sciences	and	Biotechnologies	(XXXI°	cycle);	University	of	Sassari	 43	































Giuseppe	 Marchetti;	 “In	 vitro	 and	 in	 silico	 studies	 of	 Syk	 inhibitors	 as	 new	 antimalarial	 drugs”;	Doctoral	thesis	in	Life	Sciences	and	Biotechnologies	(XXXI°	cycle);	University	of	Sassari	 45	
In	this	work,	we	performed	a	series	of	in	vitro	experiments	using	infected	RBCs	in	order	 to	 investigate	 the	biological	 activity	of	different	Syk	 inhibitors	on	P.	
falciparum	cultures	and	evaluate	their	IC50	concentrations.	We	measured	their	activity	 at	 different	 drug	 concentrations	 and	 on	 different	 parasite	 stages.	Moreover,	 in	 proteomic	 studies	 have	 been	 quantified	 the	 levels	 of	 Tyr	phosphorylation	 in	 oxidized	 RBCs	 using	 Diamide	 (sulfhydryl	 reagent	 which	oxidizes	sulfhydryl	groups	to	the	disulphide	form).	These	analyses	have	been	followed	by	 the	molecular	modelling	approach	based	on	 the	 identification	of	amino	 acidic	 interaction	 and	 the	 energy	 of	 binding	 in	 catalytic	 site	 of	 Syk	protein	 through	 the	molecular	 docking	 and	molecular	 dynamic	 studies.	 The	chemical	 characteristics	 of	 compounds	 have	 been	 analysed	 using	 the	molecular	 descriptors.	 Furthermore,	 accurate	 studies	 on	 the	 human	 kinases	crystal	 structures	 available	on	public	database	RCSB	PDB	allowed	us	 to	 gain	more	 information	about	 the	 ligands	and	 the	protein	 target.	Virtual	 screening	was	carried	out	 in	order	 to	 find	new	compounds	having	 the	same	pattern	of	interaction	in	the	catalytic	site	of	Syk,	useful	to	be	tested	in	vitro.			
3.1.	Experimental	in	vitro	studies	Experiments	were	 performed	 using	 P.	 falciparum	 (Palo	 Alto	 strain)	 cultures	(37°C	and	CO2	5%)	 in	Growth	Medium	(RPMI,	10%	H.	plasma,	20mM	HEPES	pH	 7.4,	 2%	 SAGM	 (Sodium	 Chloride,	 Adenine,	 Glucose,	 Mannitol)	 pH	 7.4,	10mM	Glucose,	40mg/ml	Gentamicin).	Both	haematocrit	and	parasitemia	were	at	 2%.	 	 Before	 each	 experiment,	 cultures	 have	 been	 synchronized	 at	 rings	stage	 with	 5%	 Sorbitol.	 	 Parasitized	 red	 blood	 cells	 with	 500	 μl	 of	 Growth	Medium	 contained	 in	 each	 well	 (24	 multiwell	 plate)	 were	 treated	 with	 Syk	inhibitor	II,	R406	(Tamatinib),	Gleevec	(Imatinib)	and	P505-15	(PRT062607)	at	concentration	(0.2,	0.8,	1,	2,	4,	8,	10	μM)	for	24h	and	48h.	The	parasitemia	was	evaluated	by	optic	microscopy	after	smears	preparation.	The	smears	have	been	 stained	 using	 a	 specific	 protocol	 containing,	 methanol	 to	 fix	 the	erythrocytes	 samples,	 eosin	 for	 the	 cytoplasm	 and	 thiazine	 in	 phosphate	 to	stain	 the	 parasites.	 The	 IC50	 of	 each	 compound	 has	 been	 calculated	 using	ICEstimator	1.2	software	[88].	
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3.1.2.	Treatment	of	Red	Blood	Cells.		Venous	blood	was	drawn	from	healthy	volunteers	following	informed	consent	and	pelleted	at	1000	g	for	10	minutes	at	room	temperature.	After	removal	of	the	buffy	coat,	RBCs	were	again	pelleted	and	washed	3	times	with	Phosphate	Buffered	Saline	(127 mM	NaCl,	2.7 mM	KCl,	8.1 mM	Na2HPO4,	1.5 mM	KH2PO4,	20 mM	 HEPES,	 1 mM	MgCl2,	 and	 pH	 7.4)	 in	 5 mM	 glucose	 (PBS	 glucose)	 to	obtain	packed	cells.	RBCs	were	suspended	at	30%	haematocrit	in	PBS	glucose	and	 it	were	pre-treated	 in	different	 experiments	with	 Syk	 inhibitor	 II,	 R406,	Gleevec	and	P505-15	at	concentration	(0.2,	0.8,	1,	2,	4,	8,	10	μM)	for	1	hour	at	37°C	in	the	dark,	and	then	treated	with	oxidant	diamide	at	2 mM	concentration	for	 45	 minutes.	 For	 all	 protocols	 described,	 untreated	 controls	 and	 treated	controls	 with	 only	 diamide	 2	 mM	 were	 processed	 identically.	 To	 prevent	
100	x	Cγ	C2	+	IC50γ	RE(%)	=	100	-	
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further	phosphorylation	of	band	3,	after	incubation	we	washed	the	cells	with	cold	buffer	and	membranes	were	immediately	prepared.		
3.1.3.	RBCs	Membrane	Preparation.		Membrane	proteins	were	prepared	at	4°C	on	ice	and	for	each	sample,	150 μL	of	packed	RBCs	was	diluted	into	1.5 mL	of	cold	haemolysis	buffer	(HB)	(5 mM	disodium	 phosphate,	 1 mM	 EDTA,	 pH	 8)	 containing	 a	 protease	 and	 a	phosphatase	 inhibitor	 cocktail.	 Thereafter	 they	 have	 been	 washed	 up	 to	 4	more	 times	 in	 the	 same	 buffer	 (until	 membranes	 became	 white)	 in	 a	refrigerated	eppendorf	microfuge	at	25000 g.	The	samples	were	stored	frozen	at	 −20°C	 until	 use.	 Membrane	 protein	 content	 was	 quantified	 using	 the	 CD	Protein	Assay	(Bio-Rad).		
3.1.4.	SDS-PAGE	Preparation	To	 perform	 one-dimensional	 electrophoresis	 (Sodium	 Dodecyl	 Sulphate	 -	PolyAcrylamide	Gel	Electrophoresis),	membrane	proteins	were	solubilised	 in	Laemmli	 Buffer	 [89]	 in	 a	 volume	 ratio	 of	 1: 1.	 30 µg	 of	 proteins	 for	 anti-phosphotyrosine;	 then	 samples	 were	 placed	 in	 thermomixer	 at	 1400	 rpm,	28°C	 for	30	minutes.	After	 that,	 the	 samples	were	put	 at	95°C	 for	5	minutes	and	 then	were	 separated	 on	8%	polyacrylamide	 gel	 under	 reducing	 and	no-reducing	conditions.	The	electrophoretic	run	was	performed	using	the	Bio-Rad	mini-protean	3	setup.			
3.1.5.	Western	blot	analyses.		Proteins	 separated	 by	 SDS-PAGE	 were	 transferred	 to	 nitrocellulose	membranes	as	previously	described	using	Trans-blot	turbo	Bio-Rad	and	then	probed	with	antibody	anti-phosphotyrosine	 (sc7020,	Santa	Cruz,	CA).	This	 is	produced	in	mouse	from	Santa	Cruz,	CA,	and	it	is	diluted	to	1 : 2000.	Secondary	antibodies	 conjugated	 to	 infrared	 fluorescent	 dyes	 excitable	 at	 680 nm	 or	800 nm	(IRDye:	anti-mouse	800 CW	926-32210,	Li-COR,	USA)	were	then	used	to	 visualize	 the	 desired	 antigens	 with	 an	 high	 performance	 laser	 scanner	(Odyssey,	 Licor,	USA).	The	quantitative	 analyses	of	 tyrosine	phosphorylation	levels	were	carried	out	and	were	measured	analysing	western	blot	images	by	
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3.2.1.	Molecular	Mechanics	(MM)	and	Quantum	Mechanics(QM)	Computational	 modelling	 was	 performed	 on	 multiprocessor	 machines,	 IBM	Blade	 Center	 HS22	 type	 7870,	 with	 OS	 Ubuntu	 16.04	 or	 Windows	 10.	 The	small	molecules	were	constructed	with	standard	bond	lengths	and	angles	from	the	 fragment	database	with	MacroModel	5.5	 [90].	Minimization	of	 structures	by	 conformational	 search	was	performed	with	 the	MacroModel/BachMin	6.0	program	using	the	AMBER	force	field.	An	extensive	conformational	 search	was	 further	carried	out	using	 the	Monte	Carlo/energy	 minimization	 [91]	 (Ei-E	 min	 <5	 Kcal/mole,	 energy	 difference	between	the	generated	conformation	and	the	current	minimum).	The	 atomic	 charges	 were	 assigned	 using	 the	 Gasteiger-Marsili	 method	 [92].	Representative	 minimum	 energy	 conformations	 of	 each	 compound	 were	optimised	using	the	quantum	chemistry	program	Gaussian	09W	with	method	DFT	 B3LYP/6-311G	 basis	 set.	 Visual	 quantum	 chemical	 calculation	 analysis	was	performed	with	GaussView	version	5.0,	[93,94].		
3.2.2.	Molecular	docking	All	 docking	 tests	 were	 performed	 considering	 a	 grid	 60	 x	 60	 x	 60	 and	 the	default	grid	spacing	(0.375	Å)	was	adopted,	treating	the	docking	active	site	as	a	rigid	and	the	 ligands	as	 flexible,	 i.e.,	all	non	rings	 torsions	were	considered	free	to	rotate.	Binding	 of	 compounds	 was	 analysed	 using	 MGLTools	 1.5.7rc1	 [95]	 and	AutoDock	4.2	docking	programs	[96,97].	From	the	estimated	free	energy	of	ligand	binding	(E.F.E.B.,	ΔG),	the	inhibition	constant	(Ki)	for	each	ligand	was	evaluated.	Ki	is	calculated	by	the	equation:	Ki	=exp	 [(ΔG*	 1000)/	 (R*T)].	Where	 ΔG	 is	 docking	 energy,	 R	 (gas	 constant)	 is	1.98719	cal	K−1	mol−1	and	T	(Temperature)	 is	298.15	K.	The	protein	 target	Syk	in	complex	with	AMP-PNP	ligand	(PDB	ID:	4FL2	with	resolution	of	2,19	Å)	
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deposited	in	RCSB	Protein	Data	Bank	[98]	was	chosen.	The	structure	was	the	most	 defined	 and	 complete	 except	 for	 the	 first	 part	 of	 N-terminus	 (a.a.	 1-8)	and	 for	 interdomain	 linker	 region	 (a.a.	 265-336).	The	 crystallographic	water	molecules	were	stripped,	hydrogen	atoms	were	added	using	ADT	module.		
	



















Giuseppe	 Marchetti;	 “In	 vitro	 and	 in	 silico	 studies	 of	 Syk	 inhibitors	 as	 new	 antimalarial	 drugs”;	Doctoral	thesis	in	Life	Sciences	and	Biotechnologies	(XXXI°	cycle);	University	of	Sassari	 51	
3.2.3.	Quantum	Mechanics	molecular	descriptors		
	
3.2.3.1.	Homo	-	Lumo	Homo-Lumo	 distribution,	 respectively	 "highest	 occupied	 molecular	 orbital"	and	 "lowest	 unoccupied	 molecular	 orbital",	 was	 computed	 evaluating	 the	energies	and	energy	gaps	for	each	compound.		The	 energy	 difference	 between	 the	 Homo	 and	 Lumo	 is	 termed	 the	HOMO–
LUMO	 gap.	 HOMO	 and	 LUMO	 are	 sometimes	 called	 frontier	 orbitals	 in	frontier	molecular	orbital	theory.	This	was	based	on	three	main	observations	of	molecular	orbital	theory	as	two	molecules	interact:		1. The	occupied	orbitals	of	different	molecules	repel	each	other.	2. Positive	charges	of	one	molecule	attract	the	negative	charges	of	the	other.	3. The	 occupied	 orbitals	 of	 one	molecule	 and	 the	 unoccupied	 orbitals	 of	 the																	other	interact	with	each	other	causing	attraction.	The	difference	 in	 energy	between	 these	 two	 frontier	 orbitals	 can	be	used	 to	predict	 the	 strength	 and	 chemical	 stability	 of	 molecules	 or	 transition	 metal	complexes,	as	well	as	the	colours	they	produce	in	solution.	The	 ligand	band	gap	 investigated	can	be	 tuned	 from	3.10	 to	6.12	eV.	 Similar	and	relatively	high	ΔE	values,	highlight	a	good	stability	of	the	inhibitors,		Frontier	orbital	energies	including	HOMO	and	LUMO	are	used	to	characterize	the	electronic	properties	of	the	compounds.	LUMO	is	directly	associated	with	the	electron	affinity	and	system’s	tendency	to	accept	electron	density,	whereas	HOMO	is	directly	associated	with	the	ionization	potential	[100,101]			
3.2.3.2.	Map	Electrostatic	Potential	(MEP)	Electrostatic	 potential	 maps,	 also	 known	 as	 electrostatic	 potential	energy	maps,	 shows	 the	 sites	 with	 abundant	 electrons	 by	 analysing	 charges	distribution	within	 a	molecule	 in	 three	 dimensions;	 it	 is	 related	with	 dipole	moment,	 electronegativity	 and	partial	 charges;	 and	 shows	 the	 reactivity	 of	 a	molecule.		Positive	potential	values	reflect	nucleus	predominance,	while	negative	values	represent	rearrangements	of	electronic	charges	and	lone	pairs	of	electrons.		
	 	 Materials	&	Methods	
Giuseppe	 Marchetti;	 “In	 vitro	 and	 in	 silico	 studies	 of	 Syk	 inhibitors	 as	 new	 antimalarial	 drugs”;	Doctoral	thesis	in	Life	Sciences	and	Biotechnologies	(XXXI°	cycle);	University	of	Sassari	 52	
The	 MEP	 allowed	 us	 to	 visualize	 variably	 charged	 regions	 of	 a	 molecule.	Knowledge	 of	 the	 charge	 distributions	 has	 been	 used	 to	 determine	 how	molecules	interact	one	with	other.	The	creation	of	electrostatic	potential	map	consists	 of	 the	 use	 of	 electrostatic	 potential	 energy,	 through	 setting	 the	distance	 from	 the	 nuclei	 of	 the	 molecules.	 Electrostatic	 potential	 energy	 is	fundamentally	a	measure	of	the	strength	of	the	nearby	charges	and	electrons,	in	 a	 particular	 position.	One	 of	 the	 purposes	 of	 finding	 the	 electrostatic	potential	is	to	investigate	the	reactive	site	of	a	molecule.	The	reactive	site	is	a	particularly	 charged	 region	 of	 a	molecule	 that	 has	 an	 affinity	 for	 interacting	with	charged	particles.	To	 accurately	 analyse	 the	 charge	 distribution	 of	 a	 molecule,	 a	 very	 large	quantity	of	electrostatic	potential	energy	values	has	been	calculated.	The	best	way	 to	 convey	 this	 data	 was	 to	 visually	 represent	 it,	 as	 in	 an	 electrostatic	potential	 map.	 To	 make	 the	 electrostatic	 potential	 energy	 data	 easy	 to	interpret,	 a	 colour	 spectrum,	 with	 red	 as	 the	 lowest	 electrostatic	 potential	energy	 value	 and	 blue	 as	 the	 highest,	 is	 employed	 to	 convey	 the	 varying	intensities	of	the	electrostatic	potential	energy	values.	
	
3.2.4.	Molecular	dynamics	(MD)	Molecular	 dynamics	 (MD)	 calculations	 were	 performed	 to	 simulate	 the	interaction,	of	 the	best	 score	conformations	predicted	by	Autodock	of	 the	all	ligands,	with	active	site	of	Syk	protein.	The	MD	protocol	 (see	Supplementary	data	 for	 details)	 for	 the	 production	 simulations	 were	 carried	 out	 using	 the	parallel	version	of	particle	mesh	ewald	molecular	dynamics	(PMEMD)	version	included	in	the	AMBER14	suite	program	[102],	after	careful	relaxation	of	the	only	system	using	minimization	and	equilibration	protocols.		1000	 time	 step	 from	 10	 nanoseconds	 of	 molecular	 dynamics	 trajectory	 of	production	is	saved.	The	ionisable	residues	were	set	to	their	normal	ionization	states	 at	 pH7,	 the	 protein	 atoms,	 as	 well	 as	 all	 the	 water	 molecules	 of	 the	crystal	structure,	were	surrounded	by	periodic	box	of	TIP3P	water	molecules	that	extended	10	Å	from	the	protein.	Counterions	(Cl-	or	Na+)	were	placed	by	xleap	 to	 neutralize	 the	 system	with	 force	 field	 for	 Ewald	 charges	 and	TIP3P	water	[103].		
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The	ff10	version	of	the	AMBER	force	field	was	used	to	model	the	protein,	and	the	 GAFF	 force	 field	 was	 used	 for	 the	 organic	 ligand.	 Using	 the	 AMBER	antechamber	program	derived	AM-BCC	partial	charges.	 In	the	MD	simulation	protocol,	 the	 time	step	was	chosen	to	be	2	 fs	 (10-15	seconds),	and	the	SHAKE	algorithm	was	used	 to	constrain	all	bonds	 involving	hydrogen	atoms.	A	non-bonded	cutoff	of	8.0	Å	was	used.	Langevin	dynamics	was	used	to	control	 the	temperature	 (300	 K)	 using	 a	 collision	 frequency	 of	 1.0	 ps-1,	 with	 isotropic	position	 scaling	 to	 maintain	 the	 pressure	 (1	 atm).	 Periodic	 boundary	conditions	 were	 applied	 to	 simulate	 a	 continuous	 system.	 To	 include	 the	contributions	 of	 long-range	 interactions,	 the	 particle	 mesh	 Ewald	 (PME)	method	was	used	with	a	grid	spacing	of	1	Å	combined	with	a	fourth-order	B-spline	 interpolation	 to	 compute	 the	potential	 and	 the	 forces	 in	between	grid	points.	The	trajectories	were	analysed	using	the	PTRAJ	module	of	AMBER.	Molecular	Mechanics	/	Poisson	Boltzmann	(or	Generalized	Born)	Surface	Area	(MM/PB(GB)SA)	calculations	and	analysis	were	made	with	the	program	MM-PBSA	of	Amber14	suite.		Graphical	 representation	 of	 the	 hypothetical	 positions	 derivative	 from	 the	docking	 calculation	 and	 analysing	 trajectory	 of	 molecular	 dynamics	calculations	 was	 performed	 using	 the	 software	 Chimera	 [104]	 and	 Visual	Molecular	Dynamics	(VMD)	[105].	Calculation	and	comparison	energy	have	been	conducted	using	the	method	of	Ross	Walker	[106].	
	
3.2.4.1.	RMSD	maps	in	Molecular	Dynamic		The	RMSD	maps	represented	in	2D	graphical	form	show	the	computation	of	all	pairwise	RMSDs	between	frames	and	collect	the	result	 in	greyscale.	The	axes	are	 the	 frame	 numbers;	 lighter	 squares	 reflect	 pairs	 of	 frames	 with	 lower	RMSDs	 (more	 similar	 structures)	 and	 darker	 squares	 reflect	 pairs	 of	 frames	with	 higher	 RMSDs	 (less	 similar	 structures).	 Precisely	 the	 lighter	 squares	show	the	conformational	families	of	ligands	or	protein.	The	RMSDs	are	directly	related	 to	 the	 conformational	 changing	 or	 variation	 within	 the	 family,	therefore	 lower	RMSD	(lighter	square)	reflect	a	minor	variation	while	higher	RMSD	(darker	square)	corresponds	to	a	major	variation	of	conformation.	The	
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3.2.5.1.	3D	alignment	superposition	of	Syk		The	structures	 superposition	has	been	conducted	picking	 the	available	X-ray	crystal	of	Syk	protein	from	public	database	(RCSB	 PDB).	 Forty-three	 Syk	 structures	were	 selected	 (forty-two	 with	 open	conformation,	 namely	 with	 opened	activation	 loop	and	only	 catalytic	 site,	 and	one	 (4FL2.pdb)	 with	 closed	 conformation	considered	 as	 the	most	 complete	 crystal),	(Tab.2).		The	 alignment	 has	 been	 performed	 using	the	 UCSF	 Chimera	 software	 and	 it	 was	based	 on	 three	 criteria	 in	 order	 to	 assess	the	flexibility	and	domain	variation.		The	 first	 criterion	 consisted	 in	 the	 use	 of	close	 (active)	 structure	 as	 reference	aligned	with	the	forty-two	remaining	open	(inactive)	structures.		The	 second	 criterion	 was	 based	 on	 the	alignment	among	an	open	conformation	as	reference	 compared	 to	 the	 forty-two	remaining	(one	closed	and	forty-one	open).	In	 the	 last	 criterion	 have	 been	 considered	as	 reference	 only	 the	 aminoacids	 that	interact	with	 the	 ligands	 into	 the	 Syk	 active	 pocket	 aligned	 to	 the	 forty-two	structures.	 Each	 alignment	 was	 examined	 through	 the	 RMSD	 (Root	 mean	
!!!X#ray!crystal!structure Conformation Resolution
Protein!(Syk) Ligand Syk Angstrom!(Å)1XBB STI open 1.571XBC STU open 23EMG 685 open 2.63FQE P5C open 2.53FQH 057 open 2.263FQS 585 open 2.13SRV S19 open 1.953TUB FPU open 2.233TUC FPW open 2.13TUD FPX open 2.333VF8 0JE open 2.083VF9 477 open 2.34DFL 0K0 open 1.984DFN 0K1 open 2.484FL2 ANP close 2.194F4P 0SB open 2.374FYN 0VE open 2.314FYO 0VF open 1.44FZ6 0VG open 1.854FZ7 0VH open 1.754GFG 0XF open 2.354I0R 1B4 open 2.14I0T 1B6 open 1.74PUZ CG9 open 2.084PV0 CG4 open 24PX6 2X6 open 1.64RSS 4MG open 1.834RX7 3YV open 1.84RX8 3YX open 1.594RX9 3YT open 1.754YJO 4DF open 1.64YJP 4DL open 1.834YJQ 4DK open 1.344YJR 4DJ open 1.324YJS 4DN open 2.224YJT 4DQ open 1.524YJU 4DO open 1.674YJV 4DT open 1.655C26 50H open 1.955C27 50J open 2.155CXH 55M open 1.95CXZ 55U open 1.75CY3 55Y open 1.76
Tab.2	 .The	 forty-three	 crystal	 structures	
analysed	 (open	 and	 close	 conformation)	
with	the	respective	x-ray	resolution.		
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square	 deviation)	 value	 obtained	 comparing	 the	 reference	 to	 the	 rest	structures.			
3.2.5.2.	UCSF	Chimera	software	UCSF	Chimera	or	Chimera	is	an	extensible	program	that	allows	creating	High-quality	 images	 and	 movies.	 It	 is	 helpful	 for	 interactive	 visualization	 and	analysis	 of	 molecular	 structures	 and	 related	 data,	 including	 density	 maps,	supramolecular	assemblies,	sequence	alignments,	docking	results,	trajectories,	and	conformational	ensembles	[107].			
3.2.6.	Cross-docking	validation	protocol	with	43	crystal	structures	of	Syk		The	validation	was	carried	out	with	the	purpose	to	identify	the	best	pose	and	interaction	 of	 ligand	 with	 the	 protein	 target	 considering	 the	 RMSD	 values	obtained	after	the	docking	analysis.	Both	forty-three	crystal	structures	of	Syk	and	the	respectively	ligands	have	been	3D	aligned	using	the	PyMOL	software.	The	 cross	 docking	 tests	 have	 been	 carried	 out	 through	 Autodock	 4.2.6.	crossing	forty-three	crystal	structures	with	forty-three	ligands.	All	tests	were	performed	considering	a	grid	80	x	60	x	60	and	the	default	grid	spacing	(0.375	Å)	 was	 adopted,	 treating	 the	 docking	 active	 site	 as	 rigid	 and	 the	 ligands	 as	flexible,	i.e.,	all	non	rings	torsions	were	considered	active	(free	to	rotate).	Each	RMSD	value	was	been	extracted	from	the	docking	results	and	the	ligands	disposition	has	been	reviewed.	An	accurate	evaluation	of	 the	success	 ligands	interaction	was	determined	in	order	to	select	the	best	and	suitable	structure	of	Syk	protein	to	use	for	the	virtual	screening.		
	
3.2.6.1.	PyMOL	software	PyMOL	is	one	of	a	few	open-source	model	visualization	tools	available	for	use	in	 structural	 biology.	 The	 Py	 part	 of	 the	 software's	 name	 refers	 to	 that	 it	extends,	and	is	extensible	by,	the	programming	language	Python.	This	tool	can	produce	 high-quality	 3D	 images	 of	 small	 molecules	 and	 biological	macromolecules,	 such	 as	 proteins.	 It	 is	 widely	 used	 as	 a	 means	 to	 raise	information	 about	 the	 protein	 and	 ligand	 structure	 and	 their	 interactions	[108,109].		
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3.2.8.	Virtual	Screening	(VS)	Virtual	screening	analysis	has	been	performed	using	Autodock	4.2.6	version.	Syk	 complexed	 with	 4-{[(3S)-1-{7-[(3,4-dimethoxyphenyl)amino][1,3]thia-zolo[5,4-d]pyrimidin-5-yl}pyrrolidin-3-yl]-carbamoyl}benzoic	acid,	0VF	ligand		(PDB	ID:	4FYO	with	resolution	of	1.4	Å)	deposited	in	RCSB	Protein	Data	Bank	has	been	chosen.	The	structure	(catalytic	site),	having	open	conformation	has	been	 employed	 as	 protein	 target.	 Virtual	 screening	 was	 conducted	 using	 a	diversity	set	of	46.840	compounds	(Cambridge	library	in	ZINC	database)	[111]	and	all	 tests	were	performed	considering	a	grid	80	x	60	x	60	and	the	default	grid	spacing	(0.375	Å)	was	adopted,	treating	the	docking	active	site	as	a	rigid	and	 the	 ligands	 as	 flexible,	 i.e.,	 all	 non	 rings	 torsions	were	 considered	active	(free	to	rotate).	The	results	have	been	analysed	applying	precise	filters	for	the	Energy	of	binding,	ligand	efficiency	and	Hbond	interaction	aimed	to	select	the	more	 suitable	 compounds	 [112].	 Ligand	 efficiency	 is	 used	 in	 drug	 discovery	research	 programs	 to	 assist	 in	 narrowing	 focus	 to	 lead	 compounds	 with	optimal	 combinations	 of	 physicochemical	 properties	 and	 pharmacological	properties	[113-115].	Mathematically,	ligand	efficiency	(LE)	can	be	defined	as	the	 ratio	of	Gibbs	 free	energy	 (ΔG)	 to	 the	number	of	non-hydrogen	atoms	of	the	compound:	 	 	 	
LE	=	(ΔG)/N	where	ΔG	=	-RTlnKi	and	N	is	the	number	of	non-hydrogen	atoms.	It	can	be		transformed	to	the	equation:	
LE	=	1.4(-logIC50)/N	Further	VS	has	been	carried	out	in	order	to	find	a	new	class	of	spleen	tyrosine	kinases	type-II	 ligands.	A	special	conformation	of	Syk	(DFG-out)	compared	to	other	 known	 has	 been	 chosen.	 It	 has	 a	 deep	 pocket	 created	 from	 the	displacement	of	three	aminoacids	DFG	(Asp512,	Phe513,	Gly514)	leading	to	a	different	disposition	of	ligands.	Among	the	Syk	x-ray	crystal	available	on	RCSB	PDB	database	has	been	picked	the	3TUB	(resolution	of	2.23	Å)	complexed	with	1-{5-[(6,7-dimethoxyquinolin-4-yl)oxy]pyridin-2-yl}-3-[(1R,2S)-2-phenyl-cyclopropyl]urea,	FPU	ligand.	The	same	filters	were	employed	for	the	ligands	selection,	 in	 order	 to	 keep	 in	 both	 systems,	 the	 identical	 condition	 of	 study	[116].	
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4.1.	In	vitro	results		
	




inhibitors	 IC50	(μΜ)	 Range	(μΜ)	 IC50	(μΜ)	 Range	(μΜ)	
P505-15	 0.83	±	0.06	 0.78	-	0.9	 0.49	±	0.07	 0.42	-	0.61	
R406	 2.62	±	0.83	 1.42	-	3.85	 0.55	±	0.19	 0.25	-	0.92	
Gleevec	 3.81	±	0.55	 3.24	-	4.95	 1.55	±	0.13	 1.32	-	1.74	
SYK	II	 5.01	±	0.44	 4.65	-	5.87	 0.9	±	0.16	 0.82	-	1.25	
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The	 highest	 efficacy	 was	 observed	 in	 Palo	 Alto	 strain	 following	 P505-15	treatment,	 the	 novel,	 highly	 selective,	 and	 orally	 bioavailable	 small	molecule	SYK	inhibitor	with	an	IC50=	1	nM,	with	anti-SYK	activity	that	is	at	least	80-fold	greater	 than	 its	 affinity	 for	 other	 kinases,	 in	 vitro	 presented	 the	 lowest	 IC50	needed	 to	 eliminate	 50%	of	 parassitemia,	 the	 IC50	 concentration	 of	 P505-15	was	0.83	μΜ	(±	0.06)	and	0.49	μΜ	(±	0.07)	at	24	and	48	hours	of	 incubation	respectively.	 Syk	 Inhibitor	 IV,	 a	 cell-permeable,	 potent	 ATP-competitive,	reversible,	 and	 highly	 selective	 inhibitor	 of	 Syk	 tyrosine	 kinase	 activity,	presents	an	IC50	of	10	nM	but	in	vitro	showed	a	different	behaviour,	in	fact	this	compound	 holds	 a	 lower	 inhibition	 activity	 compared	 to	 the	 other	 Syk	inhibitors,	its	IC50	concentration	was	the	highest.	
	
4.1.2.	Proteomic	profile	of	Tyr	phosphorylation	in	treated	RBCs		The	proteomic	approach	was	used	in	order	to	investigate	membrane	proteins	changes	under	oxidative	stress	due	to	the	P.	falciparum	infection	in	RBCs.	The	erythrocytes	were	pre-treated	with	different	concentrations	of	Syk	inhibitors	and	then	with	2mM	Diamide	(oxidant	agent)	used	to	mimic	the	physiological	condition	 of	 infected	 red	 blood	 cells.	 As	 shown	 in	 figure	 28,	 the	 inhibitors	cause	 a	 substantial	 decrease	 of	 band	 3	 phosphorylation	 (95-250	 KDa),	 the	decrease	 of	 phosphorylation	 intensity	 is	 related	 to	 the	 increasing	 amount	 of	the	inhibitors.	This	trend	is	more	evident	at	250	KDa	bands	(clusters	of	Band3).	Taken	 together,	 these	 results	 show	 that	 Syk	 inhibitors	 efficiently	 suppress	band	3	phosphorylation.	Because	of	their	action,	Syk	inhibitors	are	expected	to	substantially	reduce	the	host	cell	membrane	weakening	occurring	at	the	end	of	parasite	development.						
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	 Quantitative	analyses	carried	out	through	Odyssey	3.0	software,	confirmed	the	great	decrease	of	Tyr	phosphorylation	levels	in	band	3	residues	caused	by	Syk	protein	 (Fig.	 29).	 Samples	 treated	 with	 2mM	 Diamide	 (see	 figures	 28-29)	showed	a	high	level	of	phosphorylation	due	to	the	oxidative	stress	conditions.					
Fig.	28.	Dose	response	course	of	erythrocyte	membrane	proteins	treated	with	an	oxidant	agent	and	Syk	
inhibitors.	 Erythrocytes	 were	 treated	 with	 2mM	 diamide	 (Dia)	 and	 different	 concentrations	 of	 Syk	
inhibitors	(0-10	μM),	(panels	(a)	Gleevec,	(b)	R406,	(c)	Syk	II,	(d)	P505-15).	C	represents	the	no	treated	
control	sample.	Erythrocytes	were	separated	by	8%	SDS-PAGE,	blotted	on	nitrocellulose	membrane	and	
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Fig.	 30.	 Pattern	 of	 Syk	 inhibitors	 binding	 to	 the	 catalytic	 domain.	 A	 suitable	 compound	 needed	 to	
interact	 with	 the	 Hinge	 region	 of	 protein	 with	 2	 H-bond.	 Basic	 interactions	 must	 be	 created	 with	
hydrophobic	region	I	and	II,	the	sugar	pocket	and	the	phosphate	binding	region.		
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4.2.2.	Docking	results		X-ray	 crystal	 structure	 (2.19	 resolution,	 PDB	 accession	 number	 4FL2)	 was	found	 in	 RCSB-PDB	 database;	 this	 structure	 was	 the	 most	 complete	 in	 the	database,	 although	 it	 has	 an	 active	 site	 closer	 comparing	 with	 the	 other	structures.		Table	 5	 shows	 the	 docking	 results	 obtained	 from	 the	 crystal	 structure	 4FL2	interacting	with	Syk	inhibitors	and	clearly	evidenced	the	conserved	Hbond.			
			 		The	docking	showed	a	different	disposition	of	ligands	in	the	pocket	compared	to	the	poses	of	crystal	structures.	We	 observed	 common	 interactions	 in	 all	 Syk	 inhibitors	 of	 the	 amino	 acids	Leu377,	Val385,	Ala400,	Met448,	Met450,	Ala451,	Gly454,	Leu501	(Tab.6).					
Tab.	5.	Data	shown	represent	the	Hbond	binding	found	in	docking	analyses	from	the	different	inhibitors	
(Gleevec,	 R406,	 Syk	 II	 and	 P505-15)	 interacting	 with	 Syk	 protein.	 Hydrogen	 donor	 (HD),	 oxygen	
acceptor	 (OA),	 nitrogen	 acceptor	 (NA),	 Debie	 (D)	 and	 Angstrom	 (Å). The	 Cross-bridge	 Hbond	
interactions	with	the	same	aa	are	listed	in	bold"	
	 	 Results	&	Discussion	
Giuseppe	 Marchetti;	 “In	 vitro	 and	 in	 silico	 studies	 of	 Syk	 inhibitors	 as	 new	 antimalarial	 drugs”;	Doctoral	thesis	in	Life	Sciences	and	Biotechnologies	(XXXI°	cycle);	University	of	Sassari	 66	
																		 			An	 interesting	 hydrophobic	 interaction	 between	 Tyr525	 and	 Gleevec	 was	found.		it	represents	the	Syk	autophosphorylation	site	[118]	and	it	has	hbond	with	Lys402,	Ala451,	Arg498	and	Asp512.	R406	forms	an	h-bond	with	Leu377,	Syk	 II	 binds	 with	 Ala451	 and	 Ser511	 with	 an	 hbond	 whereas	 Glu449	 and	Asp512	 with	 two	 hbond,	 while	 P505-15	 [119]	 binds	 to	 Glu449	 and	 Ala451	through	two	hbond	as	is	evident	from	2D	diagram	representation	(Fig.32).				
R406	 Syk	II	 Gleevec	 P505-15	Leu377	*	 Leu377	 Arg338	 Leu377	Gly378	 Gly378	 Leu377	 Val385	Ser379	 Val385	 Ser379	 Ala400	Gly380	 Ala400	 Gly380	 Met448	Val385	 Lys402	 Asn381	 			Glu449	**	Ala400	 Met448	 Phe382	 Met450	Lys402	 		Glu449	**	 Val385	 			Ala451	**	Val433	 Met450	 Ala400	 Glu452	Met448	 		Ala451	*	 Lys402	*	 Gly454	Glu449	 Gly454	 Met448	 Pro455	Met450	 Pro455	 Met450	 Lys458				Ala451	**	 Lys458	 Ala451	*	 Leu501	Glu452	 Arg498	 Leu453	 	Gly454	 Leu501	 Gly454	 	Pro455	 	Ser511	*	 Arg498	*	 	Lys458	 		Asp512	**	 Asn499	 	Leu501	 	 Leu501	 	Asp512	 	 Ser511	 		 	 Asp512	*	 		 	 Tyr525	 		 	 His531	 	
Tab.	6.	Hydrophobic	interactions	and	Hbonds	between	Syk	inhibitors	and	
protein.	The	bonds	are	shown	highlighted	with	*	(1	Hbond)	and	with	**	(2	













residues	 are	 indicated	 by	 green	 dotted	 lines,	 and	 a	 crescent	 shape	 indicates	 the	 hydrophobic	
environment.			
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The	docking	results	obtained	from	the	structure	of	Syk	(4FL2)	in	complex	with	ligands	 showed	 quite	 differences	 in	 dispositions	 of	 the	 same	 compounds	compared	 to	 their	 crystal	 structures	 of	 reference.	 Although	 they	 hold	 the	common	 pattern	 of	 interaction	 with	 Syk	 known	 for	 all	 tyrosine	 kinases,	however,	 they	 present	 rotations	 and	 torsions	 in	 their	 conformation	 into	 the	site	of	binding	(Fig.	33).			
			 	These	 diversities	 might	 be	 due	 to	 the	 fact	 that	 we	 considered	 the	 crystal	structure	4FL2,	which	 is	 in	the	active	conformation	having	a	closer	receptor-binding	 pocket	 if	 compared	 to	 the	 catalytic	 site	 of	 protein	 inactive	conformation.	 The	 active	 conformation	 is	 characterised	 for	 having	 the	 Syk	
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4.2.4.	Identification	of	residues	as	new	sites	for	Syk	specificity	The	 results	 achieved	 from	 the	 sequence	 alignment	 of	 Syk	 catalytic	 site	compared	 to	 65	 kinases	 structure,	 lead	 us	 to	 the	 discovery	 of	 two	 more	important	 residues	 (Ser511	 and	 His531),	 which	 might	 have	 a	 role	 in	 Syk	specificity.	 Four	 residues	 were	 already	 known	 in	 literature	 to	 be	 site	 of	specificity	of	Syk	 	 (Met450,	Leu453,	Pro455	and	Asn457).	The	main	purpose	was	 based	 on	 the	 identification	 of	 unique	 structural	 features	 of	 Syk	 binding	pocket	 to	prioritize	 the	compounds	binding	 to	 this	 region.	To	prove	 this,	 the	principal	 residues	 having	 a	 role	 in	 the	 ligand-protein	 interaction	 have	 been	aligned.	Thereafter	was	used	 a	 software	 to	 generate	 the	 sequence	 logo.	 This	has	 been	 analysed	 considering	 the	 size,	 the	 variability	 and	 the	 position	 of	single	aminoacid.	From	this	analysis,	we	highlighted	the	known	residues	and	two	more	residues	important	for	the	Syk	specificity	as	showed	in	figure	35.		
Docking	Syk	inhibitors	 Ligand	 M.B.E	 E.F.E.B	 E.I.C,	Ki	
4FL2_Gleevec	 Gleevec	 -10,57	 -10,73	 13,65	nM	
4FL2_P505-15	 P505-15	 -7,69	 -8,81	 346,88	nM	
4FL2_R406	 R406	 -7,28	 -7,94	 1,5	μM	
4FL2_SykII	 SykII	 -6,8	 -6,95	 8,03	μM	
Tab.	 7.	Data	 reported	 show	 the	 values	 of	 Energy	 of	 binding	and	Ki	 obtained	 from	 cross-
docking	 analysis	 of	 Syk	 inhibitors	 with	 4FL2.	 M.B.E	 (Mean	 Binding	 Energy),	 E.F.E.B	
(Estimated	Free	Energy	of	Binding),	E.I.C	(Estimated	Inhibition	Constant).		
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4.2.5	Docking	validation	to	select	VS	target	(open	conformation	of	Syk)	The	method	used	for	docking	validation	protocol	has	been	helpful	to	select	the	suitable	 Syk	 structure	 performing	 for	 a	 virtual	 screening	 of	 new	molecules.	The	 first	criterion	of	selection	regard	 the	median	calculation	of	RMSD	values	obtained	 for	 each	 crystal	 structure	 interacting	with	 the	 ligands.	 The	 second	criterion	is	related	to	the	number	of	ligands	having	RMSD	<	2	and	2	<	RMSD	<	2.5	 for	 each	 crystal	 structure	 tested	 (Plot.1).	 These	 RMSD	 ranges	 were	considered	acceptable	for	a	valid	choice	of	the	most	suitable	protein	to	use	for	VS.	 Forty-three	 catalytic	domain	 structures	have	been	picked	 from	 the	RCSB	PDB	 (Protein	 Data	 Bank)	 co-crystallized	 with	 their	 respective	 ligands	 and	cross-docked	 with	 them	 (Tab.8).	 The	 best	 target	 structure	 has	 been	 chosen	
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Fig.	 36.	 3D	 structure	 surface	 of	 4FYO.pdb	 co-crystallized	
with	its	ligand	0VF.	Image	generated	with	PyMOL	software				
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The	molecular	 orbitals	HOMO-LUMO	distribution,	 energies	 and	 energy	 gaps	 for	 the	hit	molecules	were	computed	(Fig.37).																		 				 Energy	gap	between	the	HOMO	and	LUMO	was	used	to	determine	the	chemical	stability	 and	 molecular	 features	 and	 contribute	 to	 explain	 the	 biological	activity	of	the	compounds	[123].		The	 electrostatic	 potential	 maps	 computed	 shows	 the	 sites	 with	 abundant	electrons	 by	 analysing	 charge	 distribution	 within	 a	 molecule	 in	 three	dimensions;	 it	 is	 related	 with	 dipole	 moment,	 electronegativity	 and	 partial	charges	and	shows	the	reactivity	of	a	molecule.	Positive	potential	values	reflect	nucleus	 predominance,	 while	 negative	 values	 represent	 rearrangements	 of	electronic	charges	and	lone	pairs	of	electrons.		
Fig.	 37.	The	more	probable	statistically	positions	 in	molecular	Homo-Lumo	orbital	descriptor.	
Homo	 is	 the	 highest	 occupied	 molecular	 orbital	 and	 Lumo	 represent	 the	 lowest	 occupied	
molecular	orbital.			
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4.2.6.	Molecular	Dynamic	results	Molecular	 Dynamic	 results	 highlighted	 a	major	 chemical	 stability	 and	minor	conformation	 changing	 of	 ligands	 P505-15	 and	 R406	 alone	 and	 in	 complex	with	crystal	4FL2	compared	to	Gleevec	and	Syk	II	(Plot	2,3).		
Fig.	 38.	 MEP	 surface	 Syk	 inhibitors.	 The	 color	 scheme	 ranges	 from	 red	 (negative	
potential)	 via	 green	 (zero	 potential)	 to	 blue	 (positive	 potential).	 The	 unit	 of	
isosurface	potential	is	electrostatic	potential	(eV).		
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range	values,	1.8	to	2.8	Å.	 Instead,	we	observed	especially	 that	Gleevec	has	a	significant	variation	of	structure	conformation	with	a	range	values,	2	–	3.8	Å.	Thereafter	a	detailed	analysis	of	 compounds	 interaction	has	been	performed	in	order	to	establish	the	differences	among	the	ligands	disposition	into	the	Syk	catalytic	 site	 in	 MD	 and	 the	 conformations	 obtained	 in	 docking	 analysis.	 Is	evident	as	 the	 ligands	disposition	 in	all	molecular	dynamic	 tests	confirmed	a	similar	pose	and	interaction	with	Syk	protein	(Fig.39).	Furthermore,	as	can	be	seen	 from	 the	 plot	 above	 both	 ligands	 P505-15	 and	 R406	 present	 less	fluctuations,	namely	more	stability	due	to	a	better	and	strong	interaction	with	residues	into	the	pocket	
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4.2.8.	Virtual	Screening	results		The	 first	 VS	 has	 been	 performed	 with	 a	 diversity	 set	 of	 46.840	 compounds	(Cambridge	database)	using	as	protein	target	the	crystal	structure	with	open	conformation	of	Syk	(PDB	ID:	4FYO	with	resolution	of	1.4	Å)	(Fig.41).																				The	 second	 VS	 was	 conducted	 using	 a	 special	 conformation	 of	 Syk	 protein	known	 as	DFG-out	 (PDB	 ID:	 3TUB	with	 resolution	 of	 2.23	Å).	 In	 this	 crystal	structure	 is	 evident	 a	 displacement	 of	 3	 a.a.	 residues	 (Asp512,	 Phe513,	Gly514)	into	the	catalytic	site	of	Syk,	allowing	the	interaction	of	ligands	with	a	deep	pocket	previously	hidden	(Fig.42).						
Fig.	41.	3D	model	of	4FYO	structure	co-crystallized	with	its	ligand	0VF.	The	ligand	
is	represented	with	sticks	inside	the	pocket	while	the	three	residues	DFG	(Asp512,	
Phe51	 and	 Gly514)	 are	 shown	 with	 surface	 and	 are	 disposed	 to	 close	 the	 deep	
pocket.	
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Conclusion	&	Perspectives	In	 this	 study,	 we	 evaluated	 the	 behaviour	 of	 promising	 compounds	 as	 new	antimalarial	drugs	 to	block	 the	Syk	phosphorylation	events,	 in	 infected	RBCs	by	parasites,	an	essential	prerequisite	for	parasite	egression	from	the	host	cell.	Different	 methodologies	 about	 in	 vitro	 and	 in	 silico	 studies	 were	 applied	 to	generate	the	data	of	this	thesis.	
In	vitro	and	especially	through	proteomic	studies	we	noticed	a	great	decrease	of	 phosphorylation	 levels	 when	 RBCs	 were	 treated	 by	 Syk	 Inhibitors	 and	diamide.	The	biological	data	were	also	confirmed	by	the	computational	studies.	Syk	 inhibitors	 establish	 many	 interactions	 into	 the	 Syk	 protein	 pocket.	Important	 hydrogen	 bonds	 and	 hydrophobic	 interaction	 with	 aminoacid	within	 the	 binding	 pocket,	 involved	 in	 the	 inhibition	 process,	 were	 found.	Regarding	 the	 studies	 on	 Gleevec	 and	 its	 interactions	with	 Syk,	 the	 Tyr	 525	could	be	 the	key	 to	understanding	 the	best	 efficacy	of	 this	 inhibitor	 in	silico,	although	 this	 it	 is	 not	 specific	 for	 Syk.	 Furthermore,	 the	 experimental	 data	achieved	in	docking	and	molecular	dynamics	analyses	demonstrated	that	most	of	the	amino	acid	interactions	established	by	Syk	inhibitors	could	be	relevant	to	 provide	 a	 better	 chemical	 stability	 and	 a	 lower	 binding	 energy.	 All	 the	studied	 ligands	respected	the	pattern	of	 interaction	of	kinases	and	especially	interacted	with	3	amino	acids	Met450,	Leu453	and	Pro455,	which	are	of	great	importance	to	point	out	high	levels	of	Syk	specificity	[30-32].	We	did	not	find	a	high	correspondence	between	the	data	obtained	in	vitro	and	in	silico	especially	for	Gleevec.	Gleevec	has	the	 largest	 interactions	and	the	 lowest	Ki	 in	docking	results	 but	 did	 not	 evidence	 the	 same	 in	 in	 vitro	 studies.	 We	 are	 currently	investigating	the	motivations.	Probably	it	could	be	due	from	a	lot	of	biological	variables	in	the	infected	RBCs	cultures	compared	with	the	modelling	approach	(i.e.	 RBC	 membrane	 transport,	 presence	 of	 parasite,	 drugs	 concentration),	which	 could	make	more	 or	 less	 active	 this	 compounds.	 The	 inhibitors	 R406	and	P505-15	and	their	IC50,	followed	the	same	trend	both	in	vitro	and	in	silico	and	they	have	more	effectiveness.		The	 values	 of	 free	 energies	 binding	 confirmed	 the	 high	 affinity	 of	 Syk	inhibitors	 to	 the	 catalytic	 site.	 The	 Virtual	 Screening	 approach	 has	 laid	 the	foundation	 to	 develop	 novel	 and	 promising	 compounds	 having	 antimalarial	
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